Form 4: Corcept Therapeutics Executive Trades Shares
Statement of Changes in Beneficial Ownership
Corcept Therapeutics Chief Development Officer William Guyer executed a series of transactions involving company stock, including the acquisition of stock options and the sale of common stock.
Summary
- William Guyer, Chief Development Officer at Corcept Therapeutics, engaged in stock transactions on April 7, 2026.
- He acquired 20,000 stock options with an exercise price of $21.65.
- He also sold 20,000 shares of common stock at a weighted average price of $40.97.
- Following these transactions, Guyer beneficially owns 2,231 shares of common stock directly.
- The stock sale was conducted under a Rule 10b5-1 trading plan adopted on November 27, 2024.
- The filing also notes the existence of unvested restricted stock awards.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider stock transactions rather than significant company performance indicators.
Positives
- Acquisition of 20,000 stock options at a favorable exercise price of $21.65, indicating potential future upside.
- Sale of shares at a weighted average price of $40.97, realizing significant gains from the exercise price.
Negatives
- Reduction in direct beneficial ownership of common stock by 20,000 shares.
Risks
- The filing does not explicitly mention any risks associated with these transactions.
Future Outlook
The acquisition of stock options suggests a belief in the future appreciation of Corcept Therapeutics' stock price.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives managing their personal portfolios while adhering to trading regulations. The acquisition of options and subsequent sale of shares at a higher price is a typical strategy for executives to diversify holdings and realize gains.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Plan | Transaction executed under a pre-arranged trading plan designed to comply with Rule 10b5-1(c) affirmative defense conditions. | 11/27/2024 | Ensures compliance with insider trading regulations for the executive. |
Stakeholder Impact
- Shareholders may view the sale of shares by an executive with mixed sentiment, though the transaction was conducted under a pre-planned 10b5-1 strategy.
Next Steps
- The filing does not specify any immediate next steps related to these transactions.
Key Dates
| Date | Description |
|---|---|
| 11/27/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 04/07/2026 | Date of the reported stock transactions (acquisition of options and sale of common stock). |
| 04/08/2026 | Date the Form 4 was signed by the Reporting Person's attorney-in-fact. |
Keywords
Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Options, Common Stock, William Guyer, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.